Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA; Institute for Implementation Science and Population Health, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA; Institute for Implementation Science and Population Health, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA.
Lancet HIV. 2022 Feb;9(2):e91-e101. doi: 10.1016/S2352-3018(21)00291-5.
In 2020, there were an estimated 1·7 million children younger than 15 years living with HIV worldwide, but there are few data on the proportion of children living with HIV who are undiagnosed. We aimed to estimate the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe.
We conducted an analysis of data from the cross-sectional Population-based HIV Impact Assessment (PHIA) surveys from 2015 to 2017. PHIAs are nationally representative surveys measuring HIV outcomes. HIV rapid test data (with PCR confirmatory testing for children aged <18 months) were used to measure HIV prevalence among children in each country (Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe). Mothers or guardians reported previous HIV testing of children and previous results. Detection of antiretroviral medications was done using dried blood spots. Children who tested positive in the PHIA with previous negative or unknown HIV test results and without detectable antiretroviral medication blood concentrations were considered previously undiagnosed; all other children who tested positive were considered previously diagnosed. Survey weights with jackknife variance were used to generate national estimates of HIV prevalence and undiagnosed HIV in children aged 1-14 years. We also report the prevalence (weighted proportions) of antiretroviral therapy coverage and viral load suppression (<400 copies per mL).
Between 2015 and 2017, 42 248 children aged 1-14 years were included in the surveys, of whom 594 were living with HIV. Across the seven countries, the estimated weighted HIV prevalence was 0·9% (probability band 0·7-1·1) and we estimated that there were 425 000 (probability band 365 000-485 000) children living with HIV. Among all children living with HIV, 61·0% (n=259 000 [probability band 216 000-303 000]) were previously diagnosed and 39·0% (n=166 000 [128 000-204 000]) had not been previously diagnosed with HIV. Among previously diagnosed children living with HIV, 88·4% had detectable antiretroviral medication blood concentrations and 48·3% had viral load suppression. Among all children living with HIV (regardless of previous diagnosis status), 54·7% had detectable antiretroviral medication blood concentrations and 32·6% had viral load suppression.
Our findings show the uneven coverage of paediatric HIV testing across these seven countries and underscore the urgent need to address gaps in diagnosis and treatment for all children living with HIV.
None.
2020 年,全球约有 170 万 15 岁以下儿童感染艾滋病毒,但关于感染艾滋病毒的儿童中未确诊人数的数据很少。我们旨在估计斯威士兰、莱索托、马拉维、纳米比亚、坦桑尼亚、赞比亚和津巴布韦艾滋病毒感染儿童中的未确诊艾滋病毒流行率。
我们对 2015 年至 2017 年期间进行的基于人群的艾滋病毒影响评估(PHIA)的横断面数据分析。PHIA 是衡量艾滋病毒结果的全国代表性调查。使用 HIV 快速检测数据(对年龄<18 个月的儿童进行 PCR 确认检测)来衡量每个国家(斯威士兰、莱索托、马拉维、纳米比亚、坦桑尼亚、赞比亚和津巴布韦)儿童的艾滋病毒流行率。母亲或监护人报告了儿童以前的 HIV 检测情况和以前的检测结果。使用干血斑检测抗逆转录病毒药物的存在。在 PHIA 中检测呈阳性且以前的 HIV 检测结果为阴性或未知且无可检测到的抗逆转录病毒药物血药浓度的儿童被认为是以前未确诊的;所有其他检测呈阳性的儿童被认为是以前确诊的。使用刀切方差的调查权重来生成 1-14 岁儿童中艾滋病毒流行率和未确诊艾滋病毒的全国估计值。我们还报告了抗逆转录病毒治疗覆盖率和病毒载量抑制率(<400 拷贝/毫升)的流行率(加权比例)。
2015 年至 2017 年间,纳入了 42488 名 1-14 岁的儿童进行调查,其中 594 名儿童感染了艾滋病毒。在这七个国家中,估计的加权艾滋病毒流行率为 0.9%(概率带 0.7-1.1),我们估计有 425 万(概率带 365 万-485 万)儿童感染了艾滋病毒。在所有感染艾滋病毒的儿童中,61.0%(n=259000[概率带 216000-303000])以前被诊断过,39.0%(n=166000[128000-204000])以前未被诊断过艾滋病毒。在以前被诊断为感染艾滋病毒的儿童中,88.4%的儿童有可检测到的抗逆转录病毒药物血药浓度,48.3%的儿童病毒载量得到抑制。在所有感染艾滋病毒的儿童中(无论以前的诊断状态如何),54.7%的儿童有可检测到的抗逆转录病毒药物血药浓度,32.6%的儿童病毒载量得到抑制。
我们的研究结果表明,这七个国家的儿科艾滋病毒检测覆盖率参差不齐,这突出表明迫切需要解决所有感染艾滋病毒儿童的诊断和治疗差距。
无。